Public Health Strategies to Prevent and Reduce The Misuse of Steroids in Bodybuilding Communities

Main Article Content

Deepti Mamtani, Dr. Priyanka Tiwari

Abstract

The misuse of anabolic-androgenic steroids (AAS) and other appearance and performance enhancing drugs has expanded from elite sport into recreational gyms, bodybuilding spaces and social media-driven fitness cultures. AAS are medically useful in selected conditions, but non-medical use for muscularity or performance is associated with endocrine, cardiovascular, hepatic, psychiatric and infectious risks. Because bodybuilding communities are shaped by peer norms, trainer influence, product availability, body image pressure and limited trusted health services, the problem requires a public health approach rather than only an anti-doping or punitive approach. A gym-based analytical cross-sectional study framework was used. The study population comprised 300 bodybuilding and strength-training participants from selected fitness centres. A structured questionnaire assessed demographic profile, training history, motivation, peer influence, social media exposure, knowledge, perceived harm, health-seeking behaviour and willingness to use prevention services. Data were tabulated by self-reported lifetime AAS misuse status and analysed using descriptive statistics, chi-square test and odds ratio. A p value less than 0.05 was considered statistically significant. Among 300 participants, 90 were categorized as the self-reported AAS misuse group and 210 as the non-misuse group. Misuse was strongly associated with longer training experience, competition-oriented goals, peer influence, informal trainer advice, high social media exposure, low knowledge of adverse effects, low perceived harm and body image dissatisfaction. The strongest associations were observed for body image dissatisfaction, low perceived harm, informal advice and peer influence.

Article Details

How to Cite
Deepti Mamtani, Dr. Priyanka Tiwari. (2026). Public Health Strategies to Prevent and Reduce The Misuse of Steroids in Bodybuilding Communities. International Journal of Advanced Research and Multidisciplinary Trends (IJARMT), 3(2), 883–892. Retrieved from https://www.ijarmt.com/index.php/j/article/view/1008
Section
Articles

References

National Institute on Drug Abuse. Anabolic steroids and other appearance and performance enhancing drugs (APEDs) [Internet]. Bethesda (MD): National Institute on Drug Abuse; 2025 [cited 2026 Jun 3]. Available from: https://nida.nih.gov/research-topics/anabolic-steroids

World Anti-Doping Agency. International Standard: Prohibited List 2026. Montreal: World Anti-Doping Agency; 2025.

Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and metaregression analysis. Ann doi:10.1016/j.annepidem.2014.01.009. Epidemiol. 2014;24(5):383-398.

Pope HG Jr, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict. 2014;23(4):371-377.

Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341-375. doi:10.1210/er.2013-1058.

Kanayama G, Hudson JI, Pope HG Jr. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98(1-2):1-12.

Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, Pope HG Jr. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991-2002.

Pope HG Jr, Gruber AJ, Choi P, Olivardia R, Phillips KA. Muscle dysmorphia: an underrecognized form of body dysmorphic disorder. Psychosomatics. 1997;38(6):548-557.

Kanayama G, Barry S, Hudson JI, Pope HG Jr. Body image and attitudes toward male roles in anabolic-androgenic steroid users. Am J Psychiatry. 2006;163(4):697703.

LaBotz M, Griesemer BA; Council on Sports Medicine and Fitness. Use of performance-enhancing substances. Pediatrics. 2016;138(1):e20161300.

Goldberg L, Elliot DL, Clarke GN, MacKinnon DP, Moe E, Zoref L, et al. Effects of a multidimensional anabolic steroid prevention intervention: the Adolescents Training and Learning to Avoid Steroids (ATLAS) program. JAMA. 1996;276(19):1555-1562.

Elliot DL, Goldberg L, Moe EL, DeFrancesco CA, Durham MB, McGinnis W, et al. Long-term outcomes of the ATHENA (Athletes Targeting Healthy Exercise and Nutrition Alternatives) program for female high school athletes. J Alcohol Drug Educ. 2008;52(2):73-92.

Bates G, Van Hout MC, Teck JTW, McVeigh J. Treatments for people who use anabolic androgenic steroids: a scoping review. Harm Reduct J. 2019;16(1):75. doi:10.1186/s12954-019-0343-1.

Smit DL, Verdegaal T, Bond P, de Ronde W. Navigating non-medical androgen use: towards a harm reduction paradigm. Perform Enhanc Health. 2024;12:100288. doi:10.1016/j.peh.2024.100288.

National Institute for Health and Care Excellence. Needle and syringe programmes. Public health guideline PH52. London: NICE; 2014.

Similar Articles

<< < 2 3 4 5 6 7 8 9 10 11 > >> 

You may also start an advanced similarity search for this article.